YUPELRI
LAMA NEB
Revefenacin · Viatris Specialty LLC (with Theravance Biopharma)
Active Medication & Mechanism
- Revefenacin LAMA175 mcg per 3 mL unit-dose vial
Long-acting muscarinic antagonist (anticholinergic). Inhibits the M3 receptor on airway smooth muscle, producing sustained bronchodilation with once-daily dosing.
FDA-Approved Dosing by Indication
// approval varies by strength + age COPD
1/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| 175 mcg/3 mL | Adults (≥18 years) | 1 vial (175 mcg) nebulized once daily Maintenance treatment of COPD in adults. Administer via a standard jet nebulizer with a mouthpiece connected to an air compressor (studied with the PARI LC Sprint nebulizer and PARI Trek S compressor). | 175 mcg | FDA Approved |
- 175 mcg/3 mL FDA ApprovedPop · Adults (≥18 years)1 vial (175 mcg) nebulized once dailyMaintenance treatment of COPD in adults. Administer via a standard jet nebulizer with a mouthpiece connected to an air compressor (studied with the PARI LC Sprint nebulizer and PARI Trek S compressor).Total · 175 mcg
Asthma
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | All patients | — | — | Not Approved Yupelri is not indicated for asthma. |
- Any strength Not ApprovedPop · All patients—Total · — Yupelri is not indicated for asthma.
Acute Use
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | Acute bronchospasm / rescue | — | — | Not Approved Not for acute bronchospasm or rescue. Use a SABA. |
- Any strength Not ApprovedPop · Acute bronchospasm / rescue—Total · — Not for acute bronchospasm or rescue. Use a SABA.